{
  "Basic Info": [
    {
      "question_number": 1,
      "question_text": "ID2",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Provide the patient's ID2 (this ID will only be used by IMS for internal\nquality control)."
    },
    {
      "question_number": 2,
      "question_text": "ID3",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Provide the HCMI-specific anonymized ID (ID3)."
    },
    {
      "question_number": 3,
      "question_text": "Index date",
      "field_type": "Radio",
      "options": [
        "Initial pathologic diagnosis\nSample procurement\nFirst patient visit"
      ],
      "instruction_text": "Select the reference date used to calculate time intervals (e.g. days to treatment). Date of initial pathologic diagnosis is the HCMI standard and should be used unless it is unavailable. If an alternative index date is used, indicate it here and use it for all interval\ncalculations."
    }
  ],
  "Follow-up": [
    {
      "question_number": 4,
      "question_text": "Number of days from index date to date of\nlast contact",
      "field_type": "Date",
      "options": [],
      "instruction_text": "Provide the number of days from the index date to the date of last\ncontact."
    },
    {
      "question_number": 5,
      "question_text": "Patient age on index date",
      "field_type": "Date",
      "options": [],
      "instruction_text": "Provide the age (in days) of the patient on the index date.\nNote: If the patient's age is greater than 32,872 days (90 years), please\nenter 32,872."
    }
  ],
  "Demographics": [
    {
      "question_number": 6,
      "question_text": "Gender",
      "field_type": "Dropdown",
      "options": [
        "Male\nFemale\nUnspecified"
      ],
      "instruction_text": "Provide the patient's gender using the defined categories. Identification of gender is based upon self-report and may come from a form, questionnaire,\ninterview, etc."
    },
    {
      "question_number": 7,
      "question_text": "Height",
      "field_type": "Number",
      "options": [],
      "instruction_text": "Provide the patient's height, in\ncentimeters."
    },
    {
      "question_number": 8,
      "question_text": "Weight",
      "field_type": "Number",
      "options": [],
      "instruction_text": "Provide the patient's weight, in\nkilograms."
    },
    {
      "question_number": 9,
      "question_text": "Body mass index (BMI)",
      "field_type": "Number",
      "options": [],
      "instruction_text": "If the patient's height and weight are not collected, provide the\npatient's body mass index (BMI)."
    },
    {
      "question_number": 10,
      "question_text": "Race",
      "field_type": "Radio",
      "options": [
        "American Indian or Alaska Native\nAsian\nBlack or African American\nNative Hawaiian or other Pacific Islander\nWhite\nUnknown\nNot reported"
      ],
      "instruction_text": "Provide the patient's race using the defined categories.\nAmerican Indian or Alaska Native: A person having origins in any of the original peoples of North and South America (including Central America), and who maintains tribal affiliation or community attachment.\nAsian: A person having origins in any of the peoples of the Far East, Southeast Asia, or in the Indian subcontinent including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam.\nBlack or African American: A person having origins in any of the black racial groups of Africa.\nNative Hawaiian or other Pacific Islander: A person having origins on any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Island.\nWhite: A person having origins in any of the original peoples of Europe, the\nMiddle East, or North Africa."
    },
    {
      "question_number": 11,
      "question_text": "Ethnicity",
      "field_type": "Radio",
      "options": [
        "Hispanic or Latino\nNot Hispanic or Latino\nUnknown\nNot reported"
      ],
      "instruction_text": "Provide the patient's ethnicity using the defined categories.\nHispanic or Latino: A person of Mexican, Puerto Rican, Cuban, Central or South American or other Spanish culture or origin, regardless of race.\nNot Hispanic or Latino: A person not meeting the definition of Hispanic or\nLatino."
    },
    {
      "question_number": 12,
      "question_text": "Year of birth",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Provide the year of the patient's birth. If the patient was born prior\nto 1928, insert the date 1928."
    }
  ],
  "Medical History": [
    {
      "question_number": 13,
      "question_text": "Family history of cancer",
      "field_type": "Radio",
      "options": [
        "Same\nDifferent\nNone\nUnknown"
      ],
      "instruction_text": "Has a first-degree relative of the patient been diagnosed with a cancer of the same or a different\ntype?"
    },
    {
      "question_number": 14,
      "question_text": "Smoking history",
      "field_type": "Radio",
      "options": [
        "Lifelong non-smoker (<100 cigarettes smoked in a lifetime)\nCurrent smoker (includes daily and non-daily smokers)\nCurrent reformed smoker (duration not specified)\nCurrent reformed smoker for >15 years\nCurrent reformed smoker for \u226415 years"
      ],
      "instruction_text": "Indicate the patient's history of tobacco smoking as well as their current smoking status using the defined categories."
    },
    {
      "question_number": 15,
      "question_text": "Metastasis at diagnosis assessment\nstatus",
      "field_type": "Radio",
      "options": [
        "Metastatic\nNon-metastatic (confirmed)\nNon-metastatic (unconfirmed)"
      ],
      "instruction_text": "Indicate whether there was evidence of metastasis at the time\nof diagnosis of the primary tumor."
    },
    {
      "question_number": 16,
      "question_text": "Metastatic site(s) at diagnosis",
      "field_type": "Radio",
      "options": [
        "Ascites\nBone\nBrain\nBone marrow\nCerebrospinal fluid (CSF)\nCNS\nDistant nodes\nLiver"
      ],
      "instruction_text": "Indicate the site(s) of metastasis at the time of diagnosis of the primary tumor.\nNote: If the anatomic site of tumor tissue is not listed, proceed to Question 16a, otherwise, skip to Question 17."
    }
  ],
  "Biospecimens": [
    {
      "question_number": 17,
      "question_text": "Tissue sample type(s) collected for HCMI for this case",
      "field_type": "Radio",
      "options": [
        "Normal tissue\nPrimary tumor\nMetastatic\nRecurrent\nOther tissue"
      ],
      "instruction_text": "Please select all the tissue sample types submitted for HCMI with this case."
    },
    {
      "question_number": 18,
      "question_text": "Number of NORMAL tissues biospecimens collected for HCMI for\nthis case",
      "field_type": "Number",
      "options": [],
      "instruction_text": "Please provide the number of normal tissue specimens obtained for HCMI for this case.\nNote: This number is expected to be 1."
    },
    {
      "question_number": 19,
      "question_text": "Number of PRIMARY cancer tissue biospecimens collected for HCMI model development for this case",
      "field_type": "Number",
      "options": [],
      "instruction_text": "Please provide the number of primary tumor specimens obtained for HCMI for this case.\nNote: A single primary tumor biospecimen obtained that is portioned for both sequencing and model generation counts as 1 single primary tumor specimen. This number is expected to be 1."
    },
    {
      "question_number": 20,
      "question_text": "Number of METASTATIC/\nRECURRENT cancer tissue biospecimens collected for HCMI model development for this case",
      "field_type": "Number",
      "options": [],
      "instruction_text": "Please provide the number of metastatic and/or recurrent cancer biospecimens collected for HCMI for this case. Note: A biospecimen obtained from a single site at a single timepoint in progression that is portioned for both sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression that is portioned for both sequencing and model generation counts as a second\nsingle tumor specimen."
    }
  ],
  "Consent": [
    {
      "question_number": 21,
      "question_text": "Number of OTHER tissue biospecimens collected for HCMI model development for this case",
      "field_type": "Number",
      "options": [],
      "instruction_text": "Please provide the number of pre- malignant, non-malignant, or dysplastic tissue biospecimens collected for HCMI for this case. Note: A biospecimen obtained from a single site at a single timepoint in progression that is portioned for both sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression that is portioned for both sequencing and model generation counts as a\nsecond single tumor specimen."
    },
    {
      "question_number": 22,
      "question_text": "Total number of tissue biospecimens collected for HCMI for this case",
      "field_type": "Number",
      "options": [],
      "instruction_text": "Please provide the total number of tissue biospecimens collected for HCMI for this case. Note: This number should be the sum of the normal, primary tumor, metastatic/recurrent tumor, and other biospecimen counts\nabove."
    },
    {
      "question_number": 23,
      "question_text": "Normal tissue biospecimen ordinal",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Please provide a number to identify which biospecimen this is in the sequence. Note: The first biospecimen should be number \"1,\" the second\nshould be number \"2,\" etc."
    },
    {
      "question_number": 24,
      "question_text": "CMDC sample ID",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Please provide the CMDC sample ID for this biospecimen as it will appear on tubes and the Sample Submission Form transmitted to the\nBPC."
    }
  ],
  "Primary Tumor": [
    {
      "question_number": 25,
      "question_text": "BPC submitter ID (if available)",
      "field_type": "Number",
      "options": [],
      "instruction_text": "Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form\ntransmitted to the BPC."
    },
    {
      "question_number": 26,
      "question_text": "Type of normal control",
      "field_type": "Radio",
      "options": [
        "Whole blood\nBuccal cells\nBuffy coat\nLymphocytes\nExtracted DNA from blood\nExtracted DNA from saliva\nExtracted DNA from buccal cells\nExtracted DNA from normal tissue (specify)\nFFPE non-neoplastic tissue (specify)\nNon-neoplastic tissue (specify)"
      ],
      "instruction_text": "Indicate the type of normal control submitted for this case.\nNote: if normal tissue or non-neoplastic tissue is selected, proceed to Question 26a, otherwise, skip to Question 27."
    },
    {
      "question_number": 27,
      "question_text": "Normal tissue sample preservation method",
      "field_type": "Dropdown",
      "options": [
        "Cryopreserved\nFFPE\nFrozen"
      ],
      "instruction_text": "Provide the method used to preserve the normal tissue sample collected for molecular\ncharacterization."
    }
  ],
  "Treatment Info": [
    {
      "question_number": 28,
      "question_text": "ICD-10 code for primary tumor",
      "field_type": "Dropdown",
      "options": [
        "C71.0\nC71.1\nC71.3\nC71.4\nC71.5"
      ],
      "instruction_text": "Provide the ICD-10 code for the primary tumor as used to generate the ID3 for this subject.\nNote: If the ICD-10 code is not listed, proceed to Question 28a, otherwise,\nskip to Question 29"
    },
    {
      "question_number": 29,
      "question_text": "Tumor Morphology",
      "field_type": "Dropdown",
      "options": [
        "9380/3\n9382/3\n9392/3\n9400/3\n9401/3\n9421/1\n9424/3"
      ],
      "instruction_text": "Using the patient's pathology/laboratory report, provide the ICD-O-3 histology code of the primary tumor.\nNote: If the ICD-O-3 histology code of the primary tumor is not listed, proceed to Question 29a, otherwise, skip to\nQuestion 30."
    },
    {
      "question_number": 30,
      "question_text": "Tissue or organ of origin",
      "field_type": "Dropdown",
      "options": [
        "Brain\nSpinal cord\nOther (specify)"
      ],
      "instruction_text": "Using the patient's pathology/laboratory report, select the primary site of the disease.\nNote: If the primary site of the disease is not listed, proceed to Question 30a,\notherwise skip to Question 31."
    },
    {
      "question_number": 31,
      "question_text": "Histological Type",
      "field_type": "Dropdown",
      "options": [
        "Brain cancer\nOther (specify)"
      ],
      "instruction_text": "Select the surgical pathology text description of the histological tumor type.\nNote: If the histological tumor type is not listed, proceed to Question 31a,\notherwise, skip to Question 32."
    }
  ],
  "Other1": [
    {
      "question_number": 32,
      "question_text": "Brain cancer type",
      "field_type": "Dropdown",
      "options": [
        "Diffuse midline glioma (DIPG)\nEmbryonal tumor"
      ],
      "instruction_text": ""
    },
    {
      "question_number": 33,
      "question_text": "Histological subtype",
      "field_type": "Radio",
      "options": [
        "Anaplastic astrocytoma\nAnaplastic ganglioglioma\nAnaplastic oligodendroglioma\nAnaplastic pleomorphic xanthoastrocytoma\nClassic medulloblastoma\nCNS atypical teratoid/rhabdoid tumor\nCNS ganglioneuroblastoma\nCNS neuroblastoma\nDesmoplastic/nodular medulloblastoma\nEmbryonal tumor, NOS\nETMR\nIndeterminate medulloblastoma\nLarge cell/anaplastic medulloblastoma\nLower grade glioma, NOS\nMedulloblastoma with extensive nodularity\nMedulloblastoma, NOS\nMedulloepithelioma\nOligodendroglioma\nPilocytic astrocytoma\nOther (specify)"
      ],
      "instruction_text": "Using the patient's pathology/laboratory report, select the histological subtype of the primary tumor.\nNote: If the histological subtype is not listed, proceed to Question 33a, otherwise, skip to Question 34."
    },
    {
      "question_number": 34,
      "question_text": "Prior malignancy (of the same cancer type)",
      "field_type": "Radio",
      "options": [
        "Yes\nNo\nUnknown"
      ],
      "instruction_text": "Indicate whether the patient has a history of prior malignancy of the same cancer type."
    },
    {
      "question_number": 35,
      "question_text": "Prior malignancy (other cancer type)",
      "field_type": "Radio",
      "options": [
        "Yes\nNo\nUnknown"
      ],
      "instruction_text": "Indicate whether the patient has a history of prior malignancy of a\ndifferent cancer type."
    },
    {
      "question_number": 36,
      "question_text": "WHO grade: lower grade glioma",
      "field_type": "Dropdown",
      "options": [
        "WHO Grade II\nWHO Grade III"
      ],
      "instruction_text": "Indicate grade of the lower grade glioma tumor according to the WHO\nguidelines."
    },
    {
      "question_number": 37,
      "question_text": "WHO grade: diffuse midline glioma (DIPG), embryonal tumor, or\nmedulloblastoma",
      "field_type": "Text",
      "options": [
        "WHO Grade IV"
      ],
      "instruction_text": "Indicate grade of the diffuse midline glioma (DIPG), embryonal tumor, or medulloblastoma tumor according\nto the WHO guidelines."
    },
    {
      "question_number": 38,
      "question_text": "Performance status score: Karnofsky score",
      "field_type": "Radio",
      "options": [
        "100: Normal, no complaints\n90: Able to carry out normal activity, minor signs or symptoms of disease\n80: Normal activity with effort, some signs or symptoms of disease\n70: Cares for self, unable to carry on normal activity or do active work\n60: Requires occasional assistance, but is able to care for most of his/her needs\n50: Requires considerable assistance and frequent medical care\n40: Disabled, requires special care\n30: Severely disabled\n20: Very sick, requiring hospitalization\n10: Moribund, fatal processes progressing rapidly\n0: Dead",
        "Not Evaluated",
        "Unknown"
      ],
      "instruction_text": "Indicate the score from the Karnofsky Performance status scale, representing the functional capabilities of a person."
    },
    {
      "question_number": 39,
      "question_text": "Number of days from index date to the date initial score obtained for the Karnofsky performance status\nscale",
      "field_type": "Date",
      "options": [],
      "instruction_text": "Provide the number of days from the index date to the date that the Karnofsky performance status assessment was performed."
    },
    {
      "question_number": 40,
      "question_text": "Performance status score: Eastern Cooperative Oncology Group",
      "field_type": "Radio",
      "options": [
        "0 Asymptomatic\n1 Symptomatic, but fully ambulatory\n2 Symptomatic, in bed less than 50% of the day\n3 Symptomatic, in bed more than 50% of the day, but not bed-ridden\n4 Bed-ridden\n5 Dead\nNot evaluated\nUnknown"
      ],
      "instruction_text": "Indicate the ECOG functional performance status of the patient/participant."
    },
    {
      "question_number": 41,
      "question_text": "Number of days from index date to the date initial score obtained for the ECOG performance status\nscale",
      "field_type": "Date",
      "options": [],
      "instruction_text": "Provide the number of days from the index date to the date that the ECOG performance status assessment was performed."
    },
    {
      "question_number": 42,
      "question_text": "Hereditary cancer predisposition syndrome",
      "field_type": "Dropdown",
      "options": [
        "Fanconi anemia\nGorlin syndrome\nLi-Fraumeni syndrome\nLynch syndrome"
      ],
      "instruction_text": "Indicate any hereditary cancer predisposition syndromes identified in the patient."
    },
    {
      "question_number": 43,
      "question_text": "Laterality of site",
      "field_type": "Dropdown",
      "options": [
        "Right\nLeft\nMidline"
      ],
      "instruction_text": "Provide the side of the body on which the lower grade glioma first\ndeveloped."
    },
    {
      "question_number": 44,
      "question_text": "Tumor site",
      "field_type": "Radio",
      "options": [
        "Supratentorial, frontal lobe\nSupratentorial, temporal lobe\nSupratentorial, parietal lobe\nSupratentorial, occipital lobe\nPosterior fossa, cerebellum\nPosterior fossa, brain stem\nSupratentorial, not otherwise specified"
      ],
      "instruction_text": "Select the anatomic location of the lower grade glioma within the brain."
    },
    {
      "question_number": 45,
      "question_text": "Supratentorial localization",
      "field_type": "Radio",
      "options": [
        "Cerebral cortex\nDeep gray\nSpinal cord\nWhite matter\nNot listed on medical record"
      ],
      "instruction_text": "Select the location of the supratentorial tumor."
    },
    {
      "question_number": 46,
      "question_text": "Symptom related to disease that presented first",
      "field_type": "Radio",
      "options": [
        "Headaches\nMental status changes\nMotor/movement changes\nSeizures\nSensory changes\nVisual changes\nUnknown"
      ],
      "instruction_text": "Select the patient's/participant's first presenting symptom of disease."
    },
    {
      "question_number": 47,
      "question_text": "Was H3 K27 mutation analysis performed?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo\nUnknown"
      ],
      "instruction_text": "Indicate whether H3 K27 mutation analysis was performed."
    },
    {
      "question_number": 48,
      "question_text": "Was a mutation in H3 K27 identified?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo"
      ],
      "instruction_text": "Indicate whether H3 K27 mutation was identified."
    },
    {
      "question_number": 49,
      "question_text": "If H3 K27 mutation identified, in which\nvariant was it found?",
      "field_type": "Dropdown",
      "options": [
        "H3.1\nH3.3\nOther"
      ],
      "instruction_text": "Select the H3 K27 mutation identified."
    },
    {
      "question_number": 50,
      "question_text": "Was H3 K27M IHC\nperformed?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo\nUnknown"
      ],
      "instruction_text": "Indicate whether H3 K27M was assessed by immunohistochemistry (IHC)."
    },
    {
      "question_number": 51,
      "question_text": "H3 K27M expression by IHC",
      "field_type": "Dropdown",
      "options": [
        "Positive\nNegative\nEquivocal"
      ],
      "instruction_text": "Indicate the expression of H3 K27M by immunohistochemistry (IHC)."
    },
    {
      "question_number": 52,
      "question_text": "Was IDH1/2 mutation analysis performed?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo\nUnknown"
      ],
      "instruction_text": "Indicate whether mutation analysis of IDH1 or IDH2 was performed."
    },
    {
      "question_number": 53,
      "question_text": "Was a mutation in\nIDH1/2 identified?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo"
      ],
      "instruction_text": "Indicate whether an IDH1 or IDH2\nmutation was identified at testing."
    },
    {
      "question_number": 54,
      "question_text": "If IDH1/2 mutation identified, which one?",
      "field_type": "Dropdown",
      "options": [
        "IDH1 R132H\nIDH1 R132C\nIDH1 R132S\nIDH1 R132G\nIDH1 R132L"
      ],
      "instruction_text": "Select the mutation identified in IDH1/2.\nNote: If the IDH1/2 mutation is not listed, proceed to Question 54a, otherwise, skip to Question 55."
    },
    {
      "question_number": 55,
      "question_text": "What method was used to identify the IDH1/2 mutation?",
      "field_type": "Radio",
      "options": [
        "Cancer hotspot panel\nNext generation targeted sequencing\nWhole exome sequencing\nNot performed\nOther (specify)"
      ],
      "instruction_text": "Specify the method used to identify mutations.\nNote: If the method of mutation identification is not listed, proceed to Question 55a, otherwise, skip to\nQuestion 56."
    },
    {
      "question_number": 56,
      "question_text": "Was IDH1 R132H IHC\nperformed?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo\nUnknown"
      ],
      "instruction_text": "Indicate whether immunohistochemistry for IDH1\nR132H was performed."
    }
  ],
  "Other2": [
    {
      "question_number": 57,
      "question_text": "IDH1 R132H\nexpression by IHC",
      "field_type": "Dropdown",
      "options": [
        "Positive\nNegative\nEquivocal"
      ],
      "instruction_text": "Indicate the expression of IDH1 R132H per immunohistochemistry\nresults."
    },
    {
      "question_number": 58,
      "question_text": "MMR status",
      "field_type": "Radio",
      "options": [
        "Evidence of MMR mutation by sequencing\nEvidence of MMR protein loss by IHC\nMMR loss evidence hypermutation phenotype (>10mutations/Mb)\nNo evidence of MMR alteration"
      ],
      "instruction_text": "Indicate the patient's Mismatch Repair (MMR) gene mutation status."
    },
    {
      "question_number": 59,
      "question_text": "Was IDH1/2 mutation analysis performed?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo\nUnknown"
      ],
      "instruction_text": "Indicate whether mutation analysis of IDH1 or IDH2 was performed."
    },
    {
      "question_number": 60,
      "question_text": "Was a mutation in\nIDH1/2 identified?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo"
      ],
      "instruction_text": "Indicate whether an IDH1 or IDH2\nmutation was identified at testing."
    },
    {
      "question_number": 61,
      "question_text": "If IDH1/2 mutation identified, which one?",
      "field_type": "Dropdown",
      "options": [
        "IDH1 R132H\nIDH1 R132C\nIDH1 R132S\nIDH1 R132G\nIDH1 R132L"
      ],
      "instruction_text": "Select the mutation identified in IDH1/2.\nNote: If the IDH1/2 mutation is not listed, proceed to Question 61a, otherwise, skip to Question 62."
    },
    {
      "question_number": 62,
      "question_text": "What method was used to identify the mutation?",
      "field_type": "Radio",
      "options": [
        "Next generation targeted sequencing\nCancer hotspot panel\nWhole exome sequencing\nNot performed\nOther (specify)"
      ],
      "instruction_text": "Specify the method used to identify mutations.\nNote: If the method of mutation identification is not listed, proceed to Question 62a, otherwise, skip to\nQuestion 63."
    },
    {
      "question_number": 63,
      "question_text": "Was IDH1 R132H IHC\nperformed?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo\nUnknown"
      ],
      "instruction_text": "Indicate whether immunohistochemistry for IDH1\nR132H was performed."
    },
    {
      "question_number": 64,
      "question_text": "IDH1 R132H\nexpression by IHC",
      "field_type": "Dropdown",
      "options": [
        "Positive\nNegative\nEquivocal"
      ],
      "instruction_text": "Indicate the expression of IDH1 R132H per immunohistochemistry results."
    },
    {
      "question_number": 65,
      "question_text": "MMR status",
      "field_type": "Radio",
      "options": [
        "Evidence of MMR mutation by sequencing\nEvidence of MMR protein loss by IHC\nMMR loss evidence hypermutation phenotype (>10mutations/Mb)\nNo evidence of MMR alteration"
      ],
      "instruction_text": "Indicate the patient's Mismatch Repair (MMR) gene mutation status."
    },
    {
      "question_number": 66,
      "question_text": "MYCN gene amplification status",
      "field_type": "Radio",
      "options": [
        "Amplified\nNot amplified\nNot done\nUnknown"
      ],
      "instruction_text": "Indicate the amplification status of the MYCN gene."
    },
    {
      "question_number": 67,
      "question_text": "Genetically defined subclass",
      "field_type": "Radio",
      "options": [
        "WNT-activated\nSHH-activated\nNon-WNT/non-SHH activated\nNot determined"
      ],
      "instruction_text": "Select the subclass of the medulloblastoma based on molecular features."
    },
    {
      "question_number": 68,
      "question_text": "What are the markers that were used to determine WNT- or\nSHH- activation?",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Specify the genetic information used to determine the medulloblastoma subclass."
    },
    {
      "question_number": 69,
      "question_text": "Are you submitting a primary tumor tissue\nsample for this case?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo"
      ],
      "instruction_text": "If yes, proceed to question 70, otherwise, skip to Question 86."
    },
    {
      "question_number": 70,
      "question_text": "Primary tumor biospecimen ordinal",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Please provide a number to identify which biospecimen this is in the sequence.\nNote: This number should be \u201c1\u201d."
    },
    {
      "question_number": 71,
      "question_text": "CMDC sample ID",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Please provide the CMDC sample ID for this biospecimen as it will appear on tubes and the Sample Submission Form transmitted to the\nBPC."
    },
    {
      "question_number": 72,
      "question_text": "BPC submitter ID (if available)",
      "field_type": "Number",
      "options": [],
      "instruction_text": "Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form\ntransmitted to the BPC."
    },
    {
      "question_number": 73,
      "question_text": "Sample represents primary diagnosis?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo"
      ],
      "instruction_text": "Does this primary tumor specimen represent the PRIMARY DIAGNOSIS for this Case ID3?\nNote: If no, continue to Question 74. If\nyes, skip to Question 75."
    },
    {
      "question_number": 74,
      "question_text": "Specify the ICD-10 code",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Provide the ICD-10 code for the primary tumor used to generate the\nmodel submitted to HCMI."
    },
    {
      "question_number": 75,
      "question_text": "Tumor tissue sample preservation method",
      "field_type": "Dropdown",
      "options": [
        "Cryopreserved\nFFPE\nFrozen"
      ],
      "instruction_text": "Provide the method used to preserve the tumor tissue sample collected for molecular\ncharacterization."
    },
    {
      "question_number": 76,
      "question_text": "Anatomic site of tumor from which model was derived",
      "field_type": "Dropdown",
      "options": [
        "Ascites\nBone\nBone marrow\nBrain\nCerebrospinal fluid (CSF)\nLiver\nLung"
      ],
      "instruction_text": "Select the anatomic site of the tumor tissue sample used to generate the model for HCMI. Note: If the tissue or organ of origin is not listed, proceed to Question 76a. Otherwise, skip to Question 77."
    },
    {
      "question_number": 77,
      "question_text": "Method of cancer sample procurement",
      "field_type": "Dropdown",
      "options": [
        "Biopsy\nGross total resection\nSubtotal resection\nOther method (specify)"
      ],
      "instruction_text": "Provide the procedure performed to obtain the primary tumor tissue. Note: If the method of procurement is not listed, proceed to Question 77a,\notherwise, skip to Question 78."
    },
    {
      "question_number": 78,
      "question_text": "Number of days from index date to date of tumor sample procurement",
      "field_type": "Date",
      "options": [],
      "instruction_text": "Provide the number of days from the index date to the date of the procedure that produced\nthe tumor tissue submitted for\nHCMI."
    },
    {
      "question_number": 79,
      "question_text": "Tumor tissue type",
      "field_type": "Radio",
      "options": [
        "Primary\nAdditional Primary\nNOS"
      ],
      "instruction_text": "Provide the primary tumor tissue type for this sample."
    },
    {
      "question_number": 80,
      "question_text": "Primary model biospecimen ordinal",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Please provide a number to identify which biospecimen this is in the sequence.\nNote: This number is expected to be\n\u201c1\u201d."
    },
    {
      "question_number": 81,
      "question_text": "CMDC model ID",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Please provide the CMDC model ID for this sample as it will appear on tubes and the Sample Submission Form transmitted to the BPC."
    },
    {
      "question_number": 82,
      "question_text": "BPC submitter ID (if available)",
      "field_type": "Number",
      "options": [],
      "instruction_text": "Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form\ntransmitted to the BPC."
    },
    {
      "question_number": 83,
      "question_text": "Model represents primary diagnosis?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo"
      ],
      "instruction_text": "Does this MODEL represent the PRIMARY DIAGNOSIS for this Case ID3?"
    }
  ],
  "Other3": [
    {
      "question_number": 84,
      "question_text": "Model's primary tumor tissue CMDC sample ID",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Enter the CMDC Sample ID of the PRIMARY TUMOR TISSUE from\nwhich this model is derived."
    },
    {
      "question_number": 85,
      "question_text": "Model's primary tumor biospecimen ordinal",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Enter the biospecimen ordinal of the PRIMARY TUMOR TISSUE from\nwhich this model is derived."
    },
    {
      "question_number": 86,
      "question_text": "History of neoadjuvant treatment",
      "field_type": "Radio",
      "options": [
        "No\nYes",
        "radiation prior to resection\nYes",
        "pharmaceutical treatment prior to resection\nYes",
        "both radiation and pharmaceutical treatment prior to resection\nUnknown"
      ],
      "instruction_text": "Indicate whether the patient received neoadjuvant radiation or pharmaceutical treatment.\nNote: Radiation therapy is addressed in Questions 94-95. Pharmaceutical therapy is addressed in Questions 87- 93."
    },
    {
      "question_number": 87,
      "question_text": "Neoadjuvant chemotherapy type",
      "field_type": "Radio",
      "options": [
        "Cytotoxic chemotherapy\nImmunotherapy (cellular and immune checkpoint)\nTargeted therapy (small molecule inhibitors and targeted antibodies)\nNot applicable"
      ],
      "instruction_text": "Select all neoadjuvant chemotherapy types that were administered to the patient. Note: Cytotoxic chemotherapy is addressed in Questions 88-89.\nImmunotherapy is addressed in Questions 90-91 Targeted therapy is addressed in Questions 92-93."
    },
    {
      "question_number": 88,
      "question_text": "Neoadjuvant chemotherapeutic regimen",
      "field_type": "Radio",
      "options": [
        "Bevacizumab\nCarboplatin\nCarmustine\nCisplatin\nCyclophosphamide\nCytarabine\nEtoposide\nHydroxyurea\nIrinotecan"
      ],
      "instruction_text": "Select all chemotherapeutics used for neoadjuvant therapy.\nNote: If neoadjuvant chemotherapy was not given, skip to Question 90. If the neoadjuvant chemotherapeutic regimen is not listed, proceed to Question 88a, otherwise, skip to Question 89."
    },
    {
      "question_number": 89,
      "question_text": "Days to neoadjuvant chemotherapy treatment from index\ndate",
      "field_type": "Date",
      "options": [],
      "instruction_text": "Provide the number of days from index date to the date of treatment with neoadjuvant chemotherapy."
    },
    {
      "question_number": 90,
      "question_text": "Specify immunotherapy",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Provide the name of the immunotherapy administered to\nthe patient."
    },
    {
      "question_number": 91,
      "question_text": "Days to immunotherapy treatment from index\ndate",
      "field_type": "Date",
      "options": [],
      "instruction_text": "Provide the number of days from the index date to the date of treatment with immunotherapy."
    },
    {
      "question_number": 92,
      "question_text": "Specify targeted therapy",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Provide the name of the targeted therapy administered to the\npatient."
    },
    {
      "question_number": 93,
      "question_text": "Days to targeted therapy treatment\nfrom index date",
      "field_type": "Date",
      "options": [],
      "instruction_text": "Provide the number of days from the index date to the date of\ntreatment with targeted therapy."
    },
    {
      "question_number": 94,
      "question_text": "Radiation therapy administered type",
      "field_type": "Dropdown",
      "options": [
        "2D conventional\n3D conformal\nBrachytherapy HDR\nBrachytherapy LDR\nIMRT\nProton Beam"
      ],
      "instruction_text": "Provide the type of radiation therapy that was administered to the patient.\nNote: If radiation therapy was not administered, proceed to Question 96. If the radiation therapy is not listed, proceed to Question 94a, otherwise, skip to Question 95."
    },
    {
      "question_number": 95,
      "question_text": "Days to radiation treatment from index\ndate",
      "field_type": "Date",
      "options": [],
      "instruction_text": "Provide the number of days from the index date to the date of\ntreatment with radiation therapy."
    },
    {
      "question_number": 96,
      "question_text": "Are you submitting a metastatic/recurrent tumor tissue sample?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo"
      ],
      "instruction_text": "A biospecimen obtained from a single site at a single timepoint in progression that is portioned for both sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression that is portioned for both sequencing and model generation counts as a second single tumor specimen.\nNote: If yes, proceed to Question 97. If\nno, proceed to Question 199."
    },
    {
      "question_number": 97,
      "question_text": "Metastatic tissue biospecimen ordinal",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Please provide a number to identify which biospecimen this is in the sequence.\nNote: The first biospecimen should be number \"1\", the second should be\nnumber \"2\", etc."
    },
    {
      "question_number": 98,
      "question_text": "CMDC tissue ID",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Please provide the CMDC sample ID for this biospecimen as it will appear on tubes and the Sample Submission Form transmitted to the\nBPC."
    },
    {
      "question_number": 99,
      "question_text": "BPC submitter ID (if available)",
      "field_type": "Number",
      "options": [],
      "instruction_text": "Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form\ntransmitted to the BPC."
    },
    {
      "question_number": 100,
      "question_text": "Metastatic/ recurrent tumor tissue sample preservation method",
      "field_type": "Dropdown",
      "options": [
        "Cryopreserved\nFFPE\nFrozen"
      ],
      "instruction_text": "Provide the method used to preserve the metastatic/recurrent tumor tissue sample collected for\nmolecular characterization."
    },
    {
      "question_number": 101,
      "question_text": "Number of days from index date to date of diagnosis of\nmetastasis/recurrence",
      "field_type": "Date",
      "options": [],
      "instruction_text": "Provide the number of days from the index date to the date of diagnosis of metastatic/recurrent\ndisease."
    },
    {
      "question_number": 102,
      "question_text": "Method of metastatic/ recurrent cancer sample procurement",
      "field_type": "Dropdown",
      "options": [
        "Biopsy\nGross total resection\nSubtotal resection\nOther method (specify)"
      ],
      "instruction_text": "Indicate the procedure performed to obtain the metastatic/recurrent tumor tissue.\nNote: If the method of procurement is not listed, proceed to Question 102a,\notherwise, skip to Question 103."
    },
    {
      "question_number": 103,
      "question_text": "Number of days from index date to date of metastatic/ recurrent sample procurement",
      "field_type": "Date",
      "options": [],
      "instruction_text": "Provide the number of days from the index date to the date of the procedure that produced the metastatic/recurrent tumor tissue\nsubmitted for HCMI."
    },
    {
      "question_number": 104,
      "question_text": "Metastatic/recurrent site",
      "field_type": "Radio",
      "options": [
        "Ascites\nBone\nBone marrow\nBrain\nCerebrospinal fluid (CSF)\nCNS\nDistant nodes\nLiver"
      ],
      "instruction_text": "Select the site from which the metastatic/recurrent tissue used to develop the model was derived.\nNote: If the metastatic/recurrent site is not listed, proceed to Question 104a, otherwise, skip to Question 105."
    },
    {
      "question_number": 105,
      "question_text": "Site of relapse",
      "field_type": "Radio",
      "options": [
        "Local\nRegional\nDistant\nNot applicable"
      ],
      "instruction_text": "If the primary tumor relapsed, provide the site of relapse."
    },
    {
      "question_number": 106,
      "question_text": "ICD-10 code",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Provide the ICD-10 code for the metastatic/recurrent tumor used to generate the model submitted to\nHCMI."
    },
    {
      "question_number": 107,
      "question_text": "ICD-O-3 histology code",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Provide the ICD-O-3 histology code describing the morphology of the metastatic/recurrent tumor used to generate the model submitted to\nHCMI."
    },
    {
      "question_number": 108,
      "question_text": "Maintenance and/or consolidation therapy administered prior to collection of metastatic/ recurrent tissue",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Provide the name(s) of the maintenance and/or consolidation therapy administered to the patient prior to the collection of the metastatic/recurrent tissue used to develop the model."
    },
    {
      "question_number": 109,
      "question_text": "Days to start of maintenance and/or consolidation therapy from index date",
      "field_type": "Date",
      "options": [],
      "instruction_text": "Provide the number of days from the index date to the date maintenance and/or consolidation therapy started."
    },
    {
      "question_number": 110,
      "question_text": "Days to last known administration date of maintenance and/or consolidation therapy\nfrom index date",
      "field_type": "Date",
      "options": [],
      "instruction_text": "Provide the number of days from the index date to the last known date of maintenance and/or consolidation therapy."
    },
    {
      "question_number": 111,
      "question_text": "Is the patient still receiving treatment?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo\nUnknown"
      ],
      "instruction_text": "Indicate whether the patient is still undergoing maintenance and/or\nconsolidation therapy."
    }
  ],
  "Other4": [
    {
      "question_number": 112,
      "question_text": "Disease status",
      "field_type": "Radio",
      "options": [
        "No evidence of disease\nProgressive disease\nStable disease\nUnknown"
      ],
      "instruction_text": "Provide the disease status following maintenance and/or consolidation therapy."
    },
    {
      "question_number": 113,
      "question_text": "Performance status score: Karnofsky score",
      "field_type": "Radio",
      "options": [
        "100: Normal, no complaints\n90: Able to carry out normal activity, minor signs or symptoms of disease\n80: Normal activity with effort, some signs or symptoms of disease\n70: Cares for self, unable to carry on normal activity or do active work\n60: Requires occasional assistance, but is able to care for most of his/her needs\n50: Requires considerable assistance and frequent medical care\n40: Disabled, requires special care\n30: Severely disabled\n20: Very sick, requiring hospitalization\n10: Moribund, fatal processes progressing rapidly\n0: Dead",
        "Not Evaluated",
        "Unknown"
      ],
      "instruction_text": "Indicate the score from the Karnofsky Performance status scale, representing the functional capabilities of a person."
    },
    {
      "question_number": 114,
      "question_text": "Number of days from index date to the date initial score obtained for the Karnofsky performance status\nscale",
      "field_type": "Date",
      "options": [],
      "instruction_text": "Provide the number of days from the index date to the date that the Karnofsky performance status assessment was performed."
    },
    {
      "question_number": 115,
      "question_text": "Performance status score: Eastern Cooperative Oncology Group (ECOG)",
      "field_type": "Dropdown",
      "options": [
        "0 Asymptomatic\n1 Symptomatic, but fully ambulatory\n2 Symptomatic, in bed less than 50% of the day"
      ],
      "instruction_text": "Indicate the ECOG functional performance status of the patient/participant."
    },
    {
      "question_number": 116,
      "question_text": "Laterality of site",
      "field_type": "Dropdown",
      "options": [
        "Right\nLeft\nMidline"
      ],
      "instruction_text": "Provide the side of the body on which the metastatic/recurrent lower grade glioma developed."
    },
    {
      "question_number": 117,
      "question_text": "Tumor site",
      "field_type": "Radio",
      "options": [
        "Supratentorial, frontal lobe\nSupratentorial, temporal lobe\nSupratentorial, parietal lobe\nSupratentorial, occipital lobe\nPosterior fossa, cerebellum\nPosterior fossa, brain stem\nSupratentorial, not otherwise specified"
      ],
      "instruction_text": "Select the anatomic location of the lower grade glioma within the brain."
    },
    {
      "question_number": 118,
      "question_text": "Supratentorial localization",
      "field_type": "Dropdown",
      "options": [
        "Cerebral cortex\nDeep gray\nSpinal cord"
      ],
      "instruction_text": "Select the location of the supratentorial tumor."
    },
    {
      "question_number": 119,
      "question_text": "Symptom related to disease that presented first",
      "field_type": "Radio",
      "options": [
        "Headaches\nMental status changes\nMotor/movement changes\nSeizures\nSensory changes\nVisual changes\nUnknown"
      ],
      "instruction_text": "Select the patient's/participant's first presenting symptom of disease."
    },
    {
      "question_number": 120,
      "question_text": "Was H3 K27 mutation analysis performed?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo\nUnknown"
      ],
      "instruction_text": "Indicate whether H3 K27 mutation analysis was performed."
    },
    {
      "question_number": 121,
      "question_text": "Was a mutation in H3 K27 identified?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo"
      ],
      "instruction_text": "Indicate whether H3 K27 mutation was identified."
    },
    {
      "question_number": 122,
      "question_text": "If H3 K27 mutation identified, in which\nvariant was it found?",
      "field_type": "Dropdown",
      "options": [
        "H3.1\nH3.3\nOther"
      ],
      "instruction_text": "Select the H3 K27 mutation identified."
    },
    {
      "question_number": 123,
      "question_text": "Was H3 K27M IHC\nperformed?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo\nUnknown"
      ],
      "instruction_text": "Indicate whether H3 K27M was assessed by immunohistochemistry\n(IHC)."
    },
    {
      "question_number": 124,
      "question_text": "H3 K27M expression by IHC",
      "field_type": "Dropdown",
      "options": [
        "Positive\nNegative\nEquivocal"
      ],
      "instruction_text": "Indicate the expression of H3 K27M by immunohistochemistry (IHC)."
    },
    {
      "question_number": 125,
      "question_text": "Was IDH1/2 mutation analysis performed?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo\nUnknown"
      ],
      "instruction_text": "Indicate whether mutation analysis of IDH1 or IDH2 was performed."
    },
    {
      "question_number": 126,
      "question_text": "Was a mutation in\nIDH1/2 identified?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo"
      ],
      "instruction_text": ""
    },
    {
      "question_number": 127,
      "question_text": "If IDH1/2 mutation identified, which one?",
      "field_type": "Dropdown",
      "options": [
        "IDH1 R132H\nIDH1 R132C\nIDH1 R132S\nIDH1 R132G\nIDH1 R132L"
      ],
      "instruction_text": "Note: If the IDH1/2 mutation is not listed, proceed to Question 127a, otherwise, skip to Question 128."
    },
    {
      "question_number": 128,
      "question_text": "What method was used to identify the IDH1/2 mutation?",
      "field_type": "Radio",
      "options": [
        "Cancer hotspot panel\nNext generation targeted sequencing\nWhole exome sequencing\nNot performed\nOther (specify)"
      ],
      "instruction_text": "Specify the method used to identify mutations.\nNote: If the method of mutation identification is not listed, proceed to Question 128a, otherwise, skip to\nQuestion 129."
    },
    {
      "question_number": 129,
      "question_text": "Was IDH1 R132H IHC\nperformed?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo\nUnknown"
      ],
      "instruction_text": "Indicate whether immunohistochemistry for IDH1\nR132H was performed."
    },
    {
      "question_number": 130,
      "question_text": "IDH1 R132H\nexpression by IHC",
      "field_type": "Dropdown",
      "options": [
        "Positive\nNegative\nEquivocal"
      ],
      "instruction_text": "Indicate the expression of IDH1 R132H per immunohistochemistry\nresults."
    },
    {
      "question_number": 131,
      "question_text": "MMR status",
      "field_type": "Radio",
      "options": [
        "Evidence of MMR mutation by sequencing\nEvidence of MMR protein loss by IHC\nMMR loss evidence hypermutation phenotype (>10mutations/Mb)\nNo evidence of MMR alteration"
      ],
      "instruction_text": "Indicate the patient's Mismatch Repair (MMR) gene mutation status."
    },
    {
      "question_number": 132,
      "question_text": "Was IDH1/2 mutation analysis performed?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo\nUnknown"
      ],
      "instruction_text": "Indicate whether mutation analysis of IDH1 or IDH2 was performed."
    },
    {
      "question_number": 133,
      "question_text": "Was a mutation in IDH1/2 identified?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo"
      ],
      "instruction_text": "Indicate whether an IDH1 or IDH2 mutation was identified at testing."
    },
    {
      "question_number": 134,
      "question_text": "If IDH1/2 mutation identified, which one?",
      "field_type": "Dropdown",
      "options": [
        "IDH1 R132H\nIDH1 R132C\nIDH1 R132S\nIDH1 R132G\nIDH1 R132L\nIDH2 R172W\nIDH2 R172K\nIDH2 R172M\nOther (specify)"
      ],
      "instruction_text": "Select the mutation identified in IDH1/2.\nNote: If the IDH1/2 mutation is not listed, proceed to Question 134a, otherwise, skip to Question 135."
    },
    {
      "question_number": 135,
      "question_text": "What method was used to identify the mutation?",
      "field_type": "Radio",
      "options": [
        "Next generation targeted sequencing\nCancer hotspot panel\nWhole exome sequencing\nNot performed\nOther (specify)"
      ],
      "instruction_text": "Specify the method used to identify mutations.\nNote: If the method of mutation identification is not listed, proceed to Question 135a, otherwise, skip to Question 136."
    },
    {
      "question_number": 136,
      "question_text": "Was IDH1 R132H IHC\nperformed?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo\nUnknown"
      ],
      "instruction_text": "Indicate whether immunohistochemistry for IDH1\nR132H was performed."
    },
    {
      "question_number": 137,
      "question_text": "IDH1 R132H\nexpression by IHC",
      "field_type": "Dropdown",
      "options": [
        "Positive\nNegative\nEquivocal"
      ],
      "instruction_text": "Indicate the expression of IDH1 R132H per immunohistochemistry\nresults."
    },
    {
      "question_number": 138,
      "question_text": "MMR status",
      "field_type": "Radio",
      "options": [
        "Evidence of MMR mutation by sequencing\nEvidence of MMR protein loss by IHC\nMMR loss evidence hypermutation phenotype (>10mutations/Mb)\nNo evidence of MMR alteration"
      ],
      "instruction_text": "Indicate the patient's Mismatch Repair (MMR) gene mutation status."
    },
    {
      "question_number": 139,
      "question_text": "Number of days from index date to date of metastatic/ recurrent sample procurement",
      "field_type": "Date",
      "options": [],
      "instruction_text": "Provide the number of days from the index date to the date of the procedure that produced the metastatic/recurrent tumor tissue\nsubmitted for HCMI."
    },
    {
      "question_number": 140,
      "question_text": "MYCN gene amplification status",
      "field_type": "Radio",
      "options": [
        "Amplified\nNot amplified\nNot done\nUnknown"
      ],
      "instruction_text": "Indicate the amplification status of the MYCN gene."
    },
    {
      "question_number": 141,
      "question_text": "Genetically defined subclass",
      "field_type": "Radio",
      "options": [
        "WNT-activated\nSHH-activated\nNon-WNT/non-SHH activated\nNot determined"
      ],
      "instruction_text": "Select the subclass of the medulloblastoma based on molecular features."
    },
    {
      "question_number": 142,
      "question_text": "What are the markers that were used to determine WNT- or SHH- activation?",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Specify the genetic information used to determine the medulloblastoma subclass."
    },
    {
      "question_number": 143,
      "question_text": "Are you submitting an additional metastatic/ recurrent tumor tissue sample?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo"
      ],
      "instruction_text": "A biospecimen obtained from a single site at a single timepoint in progression that is portioned for both sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression that is portioned for both sequencing and model generation counts as a second single tumor specimen.\nNote: If yes, proceed to Question 144, otherwise, skip to Question 189."
    }
  ],
  "Other5": [
    {
      "question_number": 144,
      "question_text": "Metastatic tissue biospecimen ordinal",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Please provide a number to identify which biospecimen this is in the sequence.\nNote: The first biospecimen should be number \"1\", the second should be number \"2\", etc."
    },
    {
      "question_number": 145,
      "question_text": "CMDC tissue ID",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Please provide the CMDC sample ID for this biospecimen as it will appear on tubes and the Sample Submission Form transmitted to the\nBPC."
    },
    {
      "question_number": 146,
      "question_text": "BPC submitter ID (if available)",
      "field_type": "Number",
      "options": [],
      "instruction_text": "Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form\ntransmitted to the BPC."
    },
    {
      "question_number": 147,
      "question_text": "Metastatic/ recurrent tumor tissue sample preservation method",
      "field_type": "Dropdown",
      "options": [
        "Cryopreserved\nFFPE\nFrozen"
      ],
      "instruction_text": "Provide the method used to preserve the metastatic/recurrent tumor tissue sample collected for molecular characterization."
    },
    {
      "question_number": 148,
      "question_text": "Number of days from index date to date of diagnosis of metastasis/recurrence",
      "field_type": "Date",
      "options": [],
      "instruction_text": "Provide the number of days from the index date to the date of diagnosis of metastatic/recurrent disease."
    },
    {
      "question_number": 149,
      "question_text": "Method of metastatic/ recurrent cancer sample procurement",
      "field_type": "Dropdown",
      "options": [
        "Biopsy\nGross total resection\nSubtotal resection\nOther method (specify)"
      ],
      "instruction_text": "Indicate the procedure performed to obtain the metastatic/recurrent tumor tissue.\nNote: If the method of procurement is not listed, proceed to Question 149a, otherwise, skip to Question 150."
    },
    {
      "question_number": 150,
      "question_text": "Number of days from index date to date of metastatic/ recurrent sample procurement",
      "field_type": "Date",
      "options": [],
      "instruction_text": "Provide the number of days from the index date to the date of the procedure that produced the metastatic/recurrent tumor tissue submitted for HCMI."
    },
    {
      "question_number": 151,
      "question_text": "Metastatic/ recurrent site",
      "field_type": "Radio",
      "options": [
        "Ascites\nBone\nBone marrow\nBrain\nCerebrospinal fluid (CSF)\nCNS\nDistant nodes\nLiver"
      ],
      "instruction_text": "Select the site from which the metastatic/recurrent tissue used to develop the model was derived.\nNote: If the metastatic/recurrent site is not listed, proceed to Question 151a, otherwise, skip to Question 152."
    },
    {
      "question_number": 152,
      "question_text": "Site of relapse",
      "field_type": "Dropdown",
      "options": [
        "Local\nRegional"
      ],
      "instruction_text": "If the primary tumor relapsed, provide the site of relapse."
    },
    {
      "question_number": 153,
      "question_text": "ICD-10 code",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Provide the ICD-10 code for the metastatic/recurrent tumor used to generate the model submitted to\nHCMI."
    },
    {
      "question_number": 154,
      "question_text": "ICD-O-3 histology code",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Provide the ICD-O-3 histology code describing the morphology of the metastatic/recurrent tumor used to generate the model submitted to\nHCMI."
    },
    {
      "question_number": 155,
      "question_text": "Maintenance and/or consolidation therapy administered prior to collection of metastatic/ recurrent tissue",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Provide the name(s) of the maintenance and/or consolidation therapy administered to the patient prior to the collection of the metastatic/recurrent tissue used to develop the model."
    },
    {
      "question_number": 156,
      "question_text": "Days to start of maintenance and/or consolidation therapy\nfrom index date",
      "field_type": "Date",
      "options": [],
      "instruction_text": "Provide the number of days from the index date to the date maintenance and/or consolidation\ntherapy started."
    },
    {
      "question_number": 157,
      "question_text": "Days to last known administration date of maintenance and/or consolidation therapy\nfrom index date",
      "field_type": "Date",
      "options": [],
      "instruction_text": "Provide the number of days from the index date to the last known date of maintenance and/or consolidation therapy."
    },
    {
      "question_number": 158,
      "question_text": "Is the patient still receiving treatment?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo\nUnknown"
      ],
      "instruction_text": "Indicate whether the patient is still undergoing maintenance and/or\nconsolidation therapy."
    },
    {
      "question_number": 159,
      "question_text": "Disease status",
      "field_type": "Radio",
      "options": [
        "No evidence of disease\nProgressive disease\nStable disease\nUnknown"
      ],
      "instruction_text": "Provide the disease status following maintenance and/or consolidation therapy."
    },
    {
      "question_number": 160,
      "question_text": "Performance status score: Karnofsky score",
      "field_type": "Radio",
      "options": [
        "100: Normal, no complaints\n90: Able to carry out normal activity, minor signs or symptoms of disease\n80: Normal activity with effort, some signs or symptoms of disease\n70: Cares for self, unable to carry on normal activity or do active work\n60: Requires occasional assistance, but is able to care for most of his/her needs\n50: Requires considerable assistance and frequent medical care\n40: Disabled, requires special care\n30: Severely disabled\n20: Very sick, requiring hospitalization\n10: Moribund, fatal processes progressing rapidly\n0: Dead",
        "Not Evaluated",
        "Unknown"
      ],
      "instruction_text": "Indicate the score from the Karnofsky Performance status scale, representing the functional capabilities of a person."
    },
    {
      "question_number": 161,
      "question_text": "Number of days from index date to the date Karnofsky score\nobtained",
      "field_type": "Date",
      "options": [],
      "instruction_text": "Provide the number of days from the index date to the date that the Karnofsky performance status\nassessment was performed."
    },
    {
      "question_number": 162,
      "question_text": "Performance status score: Eastern Cooperative Oncology Group (ECOG)",
      "field_type": "Radio",
      "options": [
        "0 Asymptomatic\n1 Symptomatic, but fully ambulatory\n2 Symptomatic, in bed less than 50% of the day\n3 Symptomatic, in bed more than 50% of the day, but not bed-ridden\n4 Bed-ridden\n5 Dead\nNot evaluated\nUnknown"
      ],
      "instruction_text": "Indicate the ECOG functional performance status of the patient/participant."
    },
    {
      "question_number": 163,
      "question_text": "Laterality of site",
      "field_type": "Dropdown",
      "options": [
        "Right\nLeft\nMidline"
      ],
      "instruction_text": "Provide the side of the body on which the lower grade glioma first developed."
    },
    {
      "question_number": 164,
      "question_text": "Tumor site",
      "field_type": "Radio",
      "options": [
        "Supratentorial, frontal lobe\nSupratentorial, temporal lobe\nSupratentorial, parietal lobe\nSupratentorial, occipital lobe\nPosterior fossa, cerebellum\nPosterior fossa, brain stem\nSupratentorial, not otherwise specified"
      ],
      "instruction_text": "Select the anatomic location of the lower grade glioma within the brain."
    },
    {
      "question_number": 165,
      "question_text": "Supratentorial localization",
      "field_type": "Dropdown",
      "options": [
        "Cerebral cortex\nDeep gray\nSpinal cord"
      ],
      "instruction_text": "Select the location of the supratentorial tumor."
    }
  ],
  "Other6": [
    {
      "question_number": 166,
      "question_text": "Symptom related to disease that presented first",
      "field_type": "Dropdown",
      "options": [
        "Headaches\nMental status changes\nMotor/movement changes\nSeizures"
      ],
      "instruction_text": "Select the patient's/participant's first presenting symptom of disease."
    },
    {
      "question_number": 167,
      "question_text": "Was H3 K27 mutation\nanalysis performed?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo"
      ],
      "instruction_text": "Indicate whether H3 K27 mutation\nanalysis was performed."
    },
    {
      "question_number": 168,
      "question_text": "Was a mutation in H3 K27 identified?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo"
      ],
      "instruction_text": "Indicate whether H3 K27 mutation was identified."
    },
    {
      "question_number": 169,
      "question_text": "If H3 K27 mutation identified, in which\nvariant was it found?",
      "field_type": "Dropdown",
      "options": [
        "H3.1\nH3.3\nOther"
      ],
      "instruction_text": "Select the H3 K27 mutation identified."
    },
    {
      "question_number": 170,
      "question_text": "Was H3 K27M IHC\nperformed?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo\nUnknown"
      ],
      "instruction_text": "Indicate whether H3 K27M was assessed by immunohistochemistry\n(IHC)."
    },
    {
      "question_number": 171,
      "question_text": "H3 K27M expression\nby IHC",
      "field_type": "Dropdown",
      "options": [
        "Positive\nNegative"
      ],
      "instruction_text": "Indicate the expression of H3 K27M\nby immunohistochemistry (IHC)."
    },
    {
      "question_number": 172,
      "question_text": "Was IDH1/2 mutation analysis performed?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo\nUnknown"
      ],
      "instruction_text": "Indicate whether mutation analysis of IDH1 or IDH2 was performed."
    },
    {
      "question_number": 173,
      "question_text": "Was a mutation in IDH1/2 identified?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo"
      ],
      "instruction_text": "Indicate whether an IDH1 or IDH2 mutation was identified at testing."
    },
    {
      "question_number": 174,
      "question_text": "If IDH1/2 mutation identified, which one?",
      "field_type": "Dropdown",
      "options": [
        "IDH1\nR132H\nIDH1\nR132C\nIDH1\nR132S"
      ],
      "instruction_text": "Note: If the IDH1/2 mutation is not listed, proceed to Question 174a, otherwise, skip to Question 175."
    },
    {
      "question_number": 175,
      "question_text": "What method was used to identify the IDH1/2 mutation?",
      "field_type": "Radio",
      "options": [
        "Cancer hotspot panel\nNext generation targeted sequencing\nWhole exome sequencing\nNot performed\nOther (specify)"
      ],
      "instruction_text": "Specify the method used to identify mutations.\nNote: If the method of mutation identification is not listed, proceed to Question 175a, otherwise, skip to\nQuestion 176."
    },
    {
      "question_number": 176,
      "question_text": "Was IDH1 R132H IHC\nperformed?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo\nUnknown"
      ],
      "instruction_text": ""
    },
    {
      "question_number": 177,
      "question_text": "IDH1 R132H\nexpression by IHC",
      "field_type": "Dropdown",
      "options": [
        "Positive\nNegative\nEquivocal"
      ],
      "instruction_text": ""
    },
    {
      "question_number": 178,
      "question_text": "MMR status",
      "field_type": "Radio",
      "options": [
        "Evidence of MMR mutation by sequencing\nEvidence of MMR protein loss by IHC\nMMR loss evidence hypermutation phenotype (>10mutations/Mb)\nNo evidence of MMR alteration"
      ],
      "instruction_text": "Evidence of MMR mutation by sequencing\nEvidence of MMR protein loss by IHC\nMMR loss evidence hypermutation phenotype (>10mutations/Mb)\nNo evidence of MMR alteration"
    },
    {
      "question_number": 179,
      "question_text": "Was IDH1/2 mutation analysis performed?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo\nUnknown"
      ],
      "instruction_text": ""
    },
    {
      "question_number": 180,
      "question_text": "Was a mutation in\nIDH1/2 identified?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo"
      ],
      "instruction_text": ""
    },
    {
      "question_number": 181,
      "question_text": "If IDH1/2 mutation identified, which one?",
      "field_type": "Dropdown",
      "options": [
        "IDH1\nR132H\nIDH1\nR132C\nIDH1\nR132S"
      ],
      "instruction_text": "IDH2\nR172K\nIDH2\nR172M\nOther\n(specify)"
    },
    {
      "question_number": 182,
      "question_text": "What method was used to identify the mutation?",
      "field_type": "Radio",
      "options": [
        "Next generation targeted sequencing\nCancer hotspot panel\nWhole exome sequencing\nNot performed\nOther (specify)"
      ],
      "instruction_text": "Next generation targeted sequencing\nCancer hotspot panel\nWhole exome sequencing\nNot performed\nOther (specify)"
    },
    {
      "question_number": 183,
      "question_text": "Was IDH1 R132H IHC\nperformed?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo\nUnknown"
      ],
      "instruction_text": ""
    },
    {
      "question_number": 184,
      "question_text": "IDH1 R132H\nexpression by IHC",
      "field_type": "Dropdown",
      "options": [
        "Positive\nNegative\nEquivocal"
      ],
      "instruction_text": ""
    },
    {
      "question_number": 185,
      "question_text": "MMR status",
      "field_type": "Radio",
      "options": [
        "Evidence of MMR mutation by sequencing\nEvidence of MMR protein loss by IHC\nMMR loss evidence hypermutation phenotype (>10mutations/Mb)\nNo evidence of MMR alteration"
      ],
      "instruction_text": "Evidence of MMR mutation by sequencing\nEvidence of MMR protein loss by IHC\nMMR loss evidence hypermutation phenotype (>10mutations/Mb)\nNo evidence of MMR alteration"
    },
    {
      "question_number": 186,
      "question_text": "MYCN gene\namplification status",
      "field_type": "Radio",
      "options": [
        "Amplified\nNot amplified"
      ],
      "instruction_text": ""
    },
    {
      "question_number": 187,
      "question_text": "Genetically defined subclass",
      "field_type": "Radio",
      "options": [
        "WNT-activated\nSHH-activated\nNon-WNT/non-SHH activated\nNot determined"
      ],
      "instruction_text": "WNT-activated\nSHH-activated\nNon-WNT/non-SHH activated\nNot determined"
    },
    {
      "question_number": 188,
      "question_text": "What are the markers that were used to determine WNT- or\nSHH- activation?",
      "field_type": "Text",
      "options": [],
      "instruction_text": ""
    },
    {
      "question_number": 189,
      "question_text": "METASTATIC/\nRECURRENT model biospecimen ordinal",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Please provide a number to identify which biospecimen this is in the sequence.\nNote: The first biospecimen should be number \"1,\" the second should be\nnumber \"2,\" etc."
    },
    {
      "question_number": 190,
      "question_text": "CMDC model ID",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Please provide the CMDC model ID for this sample as it will appear on tubes and the Sample Submission\nForm transmitted to the BPC."
    },
    {
      "question_number": 191,
      "question_text": "BPC submitter ID (if available)",
      "field_type": "Number",
      "options": [],
      "instruction_text": "Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form\ntransmitted to the BPC."
    },
    {
      "question_number": 192,
      "question_text": "Model's METASTATIC/ RECURRENT tumor tissue CMDC sample\nID",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Enter the CMDC Sample ID of the METASTATIC/RECURRENT tissue\nfrom which this model is derived."
    },
    {
      "question_number": 193,
      "question_text": "Model's METASTATIC/ RECURRENT tumor tissue biospecimen\nordinal",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Enter the biospecimen ordinal of the METASTATIC/RECURRENT tissue from which this model is derived."
    },
    {
      "question_number": 194,
      "question_text": "METASTATIC/\nRECURRENT model biospecimen ordinal",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Please provide a number to identify which biospecimen this is in the sequence.\nNote: The first biospecimen should be number \"1,\" the second should be\nnumber \"2,\" etc."
    },
    {
      "question_number": 195,
      "question_text": "CMDC model ID",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Please provide the CMDC model ID for this sample as it will appear on tubes and the Sample Submission\nForm transmitted to the BPC."
    },
    {
      "question_number": 196,
      "question_text": "BPC submitter ID (if available)",
      "field_type": "Number",
      "options": [],
      "instruction_text": "Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form\ntransmitted to the BPC."
    },
    {
      "question_number": 197,
      "question_text": "Model's METASTATIC/ RECURRENT tumor tissue CMDC sample\nID",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Enter the CMDC Sample ID of the METASTATIC/RECURRENT tissue\nfrom which this model is derived."
    },
    {
      "question_number": 198,
      "question_text": "Model's METASTATIC/ RECURRENT tumor tissue biospecimen\nordinal",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Enter the biospecimen ordinal of the METASTATIC/RECURRENT tissue from which this model is derived."
    },
    {
      "question_number": 199,
      "question_text": "Are you submitting an OTHER tissue sample?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo"
      ],
      "instruction_text": "Indicate whether an OTHER tissue sample (e.g. pre-malignant, non- malignant, dysplastic tissue, etc.) was collected for HCMI for this case.\nNote: If yes, proceed to Question 200."
    },
    {
      "question_number": 200,
      "question_text": "OTHER tissue biospecimen ordinal",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Please provide a number to identify which biospecimen this is in the sequence.\nNote: The first biospecimen should be number \"1,\" the second should be number \"2,\" etc."
    },
    {
      "question_number": 201,
      "question_text": "CMDC sample ID",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Please provide the CMDC sample ID for this specimen as it will appear on tubes and the Sample Submission Form transmitted to the\nBPC."
    },
    {
      "question_number": 202,
      "question_text": "BPC submitter ID (if available)",
      "field_type": "Number",
      "options": [],
      "instruction_text": "Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form\ntransmitted to the BPC."
    },
    {
      "question_number": 203,
      "question_text": "OTHER tissue sample preservation method",
      "field_type": "Dropdown",
      "options": [
        "Cryopreserved\nFFPE\nFrozen"
      ],
      "instruction_text": "Provide the method used to preserve the OTHER tissue sample collected for molecular\ncharacterization."
    },
    {
      "question_number": 204,
      "question_text": "Method of OTHER tissue sample procurement",
      "field_type": "Dropdown",
      "options": [
        "Biopsy\nOther method (specify)"
      ],
      "instruction_text": "Indicate the procedure performed to obtain the OTHER tissue.\nNote: If the method of procurement is not listed, proceed to Question 204a,\notherwise, skip to Question 205."
    },
    {
      "question_number": 205,
      "question_text": "Number of days from index date to date of metastatic/ recurrent sample procurement",
      "field_type": "Date",
      "options": [],
      "instruction_text": "Provide the number of days from the index date to the date of the procedure that produced the metastatic/recurrent tumor tissue\nsubmitted for HCMI."
    },
    {
      "question_number": 206,
      "question_text": "Tissue type",
      "field_type": "Radio",
      "options": [
        "Non-malignant\nOther (specify)"
      ],
      "instruction_text": "Indicate the OTHER tissue type. Note: If the OTHER tissue type is not listed, proceed to Question 206a, otherwise, skip to Question 207."
    },
    {
      "question_number": 207,
      "question_text": "Anatomic site of OTHER tissue",
      "field_type": "Radio",
      "options": [
        "Ascites\nBone\nBone marrow\nBrain\nCerebrospinal fluid (CSF)\nCNS\nDistant nodes\nLiver"
      ],
      "instruction_text": "Select the site from which the OTHER tissue used to develop the model was derived.\nNote: If the OTHER tissue site is not listed, proceed to Question 207a, otherwise, skip to Question 208."
    },
    {
      "question_number": 208,
      "question_text": "ICD-10 code",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Provide the ICD-10 code for the OTHER tissue used to generate the model submitted to HCMI."
    },
    {
      "question_number": 209,
      "question_text": "ICD-O-3 histology code",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Provide the ICD-O-3 histology code describing the morphology of the OTHER tissue used to generate the model submitted to HCMI."
    },
    {
      "question_number": 210,
      "question_text": "Are you submitting an additional OTHER tissue sample?",
      "field_type": "Radio",
      "options": [
        "Yes\nNo"
      ],
      "instruction_text": "Indicate whether an OTHER tissue sample (e.g. pre-malignant, non- malignant, or dysplastic tissue, etc.) was collected for HCMI for this case. Note: If yes, proceed to Question 211,\notherwise, skip to Question 221."
    },
    {
      "question_number": 211,
      "question_text": "OTHER tissue biospecimen ordinal",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Please provide a number to identify which biospecimen this is in the sequence.\nNote: The first biospecimen should be number \"1,\" the second should be\nnumber \"2,\" etc."
    },
    {
      "question_number": 212,
      "question_text": "CMDC sample ID",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Please provide the CMDC sample ID for this specimen as it will appear on tubes and the Sample Submission Form transmitted to the BPC."
    },
    {
      "question_number": 213,
      "question_text": "BPC submitter ID (if available)",
      "field_type": "Number",
      "options": [],
      "instruction_text": "Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form\ntransmitted to the BPC."
    },
    {
      "question_number": 214,
      "question_text": "OTHER tissue sample preservation method",
      "field_type": "Dropdown",
      "options": [
        "Cryopreserved\nFFPE\nFrozen"
      ],
      "instruction_text": "Provide the method used to preserve the OTHER tissue sample collected for molecular characterization."
    },
    {
      "question_number": 215,
      "question_text": "Method of OTHER tissue sample procurement",
      "field_type": "Dropdown",
      "options": [
        "Biopsy\nOther method (specify)"
      ],
      "instruction_text": "Indicate the procedure performed to obtain the metastatic/recurrent tumor tissue.\nNote: If the method of procurement is not listed, proceed to Question 215a,\notherwise, skip to Question 216."
    },
    {
      "question_number": 216,
      "question_text": "Number of days from index date to date of metastatic/ recurrent sample procurement",
      "field_type": "Date",
      "options": [],
      "instruction_text": "Provide the number of days from the index date to the date of the procedure that produced the metastatic/recurrent tumor tissue\nsubmitted for HCMI."
    },
    {
      "question_number": 217,
      "question_text": "Tissue type",
      "field_type": "Radio",
      "options": [
        "Non-malignant\nOther (specify)"
      ],
      "instruction_text": "Indicate the OTHER tissue type. Note: If the OTHER tissue type is not listed, proceed to Question 217a, otherwise, skip to Question 218."
    },
    {
      "question_number": 218,
      "question_text": "Anatomic site of OTHER tissue",
      "field_type": "Radio",
      "options": [
        "Ascites\nBone\nBone marrow\nBrain\nCerebrospinal fluid (CSF)\nCNS\nDistant nodes\nLiver"
      ],
      "instruction_text": "Select the site from which the OTHER tissue used to develop the model was derived.\nNote: If the OTHER tissue site is not listed, proceed to Question 218a, otherwise, skip to Question 219."
    },
    {
      "question_number": 219,
      "question_text": "ICD-10 code",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Provide the ICD-10 code for the OTHER tissue used to generate the\nmodel submitted to HCMI."
    },
    {
      "question_number": 220,
      "question_text": "ICD-O-3 histology code",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Provide the ICD-O-3 histology code describing the morphology of the OTHER tissue used to generate the model submitted to HCMI."
    },
    {
      "question_number": 221,
      "question_text": "OTHER tissue model biospecimen ordinal",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Please provide a number to identify which biospecimen this is in the sequence.\nNote: The first biospecimen should be number \"1,\" the second should be\nnumber \"2,\" etc."
    }
  ],
  "Other7": [
    {
      "question_number": 222,
      "question_text": "CMDC model ID",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Please provide the CMDC model ID for this sample as it will appear on tubes and the Sample Submission\nForm transmitted to the BPC."
    },
    {
      "question_number": 223,
      "question_text": "BPC submitter ID (if available)",
      "field_type": "Number",
      "options": [],
      "instruction_text": "Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form\ntransmitted to the BPC."
    },
    {
      "question_number": 224,
      "question_text": "Model's OTHER tissue CMDC sample ID",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Enter the CMDC Sample ID of the OTHER tissue from which this model\nis derived."
    },
    {
      "question_number": 225,
      "question_text": "Model's OTHER tissue biospecimen ordinal",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Enter the biospecimen ordinal of the OTHER tissue from which this\nmodel is derived."
    },
    {
      "question_number": 226,
      "question_text": "OTHER tissue model biospecimen ordinal",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Please provide a number to identify which biospecimen this is in the sequence.\nNote: The first biospecimen should be number \"1,\" the second should be\nnumber \"2,\" etc."
    },
    {
      "question_number": 227,
      "question_text": "CMDC model ID",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Please provide the CMDC model ID for this sample as it will appear on tubes and the Sample Submission\nForm transmitted to the BPC."
    },
    {
      "question_number": 228,
      "question_text": "BPC submitter ID (if available)",
      "field_type": "Number",
      "options": [],
      "instruction_text": "Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form\ntransmitted to the BPC."
    },
    {
      "question_number": 229,
      "question_text": "Model's OTHER tissue CMDC sample ID",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Enter the CMDC Sample ID of the OTHER tissue from which this model\nis derived."
    },
    {
      "question_number": 230,
      "question_text": "Model's OTHER tissue biospecimen ordinal",
      "field_type": "Text",
      "options": [],
      "instruction_text": "Enter the biospecimen ordinal of the OTHER tissue from which this\nmodel is derived."
    }
  ]
}